MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') would like to advise that it has dispatched the following documentation related to the General Meeting of shareholders to be held at 3:00pm (AWST) on Monday, 18 March 2024 at Suite 1, 295 Rokeby Road, Subiaco Western Australia 6008, to eligible shareholders.

Contact:

Roby Zomer

Tel: +61 8 6382 3390

Email: info@mgcpharma.co.uk

Rowan Harland

Tel: +61 8 6382 3390

Email: info@mgcpharma.co.uk

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a prominent European pharmaceutical company with a strong commitment to creating accessible and ethically produced cutting-edge medicines. Our approach combines in-house research with innovative technologies, all aimed at discovering and producing treatments for currently unmet medical conditions.

Our central business strategy revolves around the development and supply of innovative medicines, responding to the increasing demand in the medical markets of Europe, North America, and Australasia.

MGC Pharma maintains a robust development pipeline that addresses two prevalent medical conditions, with additional products currently in the developmental stages. We've established strategic partnerships with renowned institutions and academia, fostering the optimization of our medicines' development. These medicines are produced in our EU-GMP Certified manufacturing facilities, ensuring the highest quality standards.

With a growing patient base in key regions like the USA, UK, Australia, and Ireland, MGC Pharma has also built a global distribution network through a wide-reaching group of commercial partners. This extensive network places us in a prime position to supply the global market effectively.

(C) 2024 Electronic News Publishing, source ENP Newswire